Bupivacaine implant - Innocoll

Drug Profile

Bupivacaine implant - Innocoll

Alternative Names: B-Implant; Bupivacaine HCl collagen-matrix implant - Innocoll; Bupivacaine-collagen bioresorbable implant - Innocoll; CollaRx® Bupivacaine implant; INL-001; INN-LD-01; XaraColl

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Innocoll
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain
  • No development reported Pain

Most Recent Events

  • 24 Jul 2017 Innocoll has been acquired by Gurnet point capital
  • 25 May 2017 Innocoll initiates enrolment in a phase II trial for Postoperative pain in USA (NCT03234374)
  • 29 Mar 2017 Innocoll intends to resubmit an NDA for bupivacaine implant for Postoperative pain at the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top